4892 — Cyfuse Biomedical KK Income Statement
0.000.00%
Last trade - 00:00- ¥6bn
- ¥3bn
- ¥61m
Annual income statement for Cyfuse Biomedical KK, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 137 | 708 | 374 | 61.1 |
| Cost of Revenue | ||||
| Gross Profit | 67 | 571 | 241 | 37.7 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 510 | 638 | 838 | 759 |
| Operating Profit | -372 | 70.6 | -464 | -697 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -327 | 145 | -472 | -586 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -330 | 143 | -474 | -589 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -330 | 143 | -474 | -589 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -330 | 143 | -474 | -589 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -46 | 19.9 | -57.7 | -75.4 |
| Dividends per Share |